News Column

Researchers at Soochow University Target DNA Vaccines (M cell-targeting strategy facilitates mucosal immune response and enhances protection against...

September 10, 2014



Researchers at Soochow University Target DNA Vaccines (M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine)

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Jiangsu, People's Republic of China, by NewsRx journalists, research stated, "Efficient delivery of antigen to mucosal associated lymphoid tissue is a first and critical step for successful induction of mucosal immunity by vaccines. Considering its potential transcytotic capability, M cell has become a more and more attractive target for mucosal vaccines."

The news reporters obtained a quote from the research from Soochow University, "In this research, we designed an M cell-targeting strategy by which mucosal delivery system chitosan (CS) was endowed with M cell-targeting ability via conjugating with a CPE30 peptide, C terminal 30 amino acids of clostridium perfringens enterotoxin (CPE), and then evaluated its immune-enhancing ability in the context of coxsackievirus B3 (CVB3)-specific mucosal vaccine consisting of CS and a plasmid encoding CVB3 predominant antigen VP1. It had shown that similar to CS-pVP1, M cell-targeting CPE30-CS-pVP1 vaccine appeared a uniform spherical shape with about 300 nm diameter and +22 mV zeta potential, and could efficiently protect DNA from DNase I digestion. Mice were orally immunized with 4 doses of CPE30-CS-pVP1 containing 50 mu g pVP1 at 2-week intervals and challenged with CVB3 4 weeks after the last immunization. Compared with CS-pVP1 vaccine, CPE30-CS-pVP1 vaccine had no obvious impact on CVB3-specific serum IgG level and splenic T cell immune responses, but significantly increased specific fecal SIgA level and augmented mucosal T cell immune responses. Consequently, much milder myocarditis and lower viral load were witnessed in CPE30-CS-pVP1 immunized group."

According to the news reporters, the research concluded: "The enhanced immunogenicity and immunoprotection were associated with the M cell-targeting ability of CPE30-CS-pVP1 which improved its mucosal uptake and transcytosis."

For more information on this research see: M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine. Vaccine, 2014;32(35):4457-4465. Vaccine can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)

Our news correspondents report that additional information may be obtained by contacting T. Ye, Soochow Univ, Inst Biol & Med Sci, Jiangsu Prov Key Lab Infect & Immun, Suzhou 215123, Jiangsu, People's Republic of China. Additional authors for this research include Y. Yue, X.M. Fan, C.S. Dong, W. Xu and S.D. Xiong (see also Biotechnology).

Keywords for this news article include: Jiangsu, People's Republic of China, Asia, Biological Products, Biotechnology, Cardiology, Cardiomyopathies, Cardiovascular, DNA Research, DNA Vaccines, Heart Disease, Immunization, Medical Devices, Myocarditis, Synthetic Vaccines, Vaccination, Viral Vaccines

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters